Private equity is thriving in gastroenterology, with several equity-backed management groups taking over the market.
The number of private equity gastrointestinal groups grew by 28 percent, to 68, in 2021, according to a report jointly published by consulting firm Fraser Healthcare and pharma research firm Spherix Global Insights.